Pathophysiology of cancer therapy-provoked atrial fibrillation

Cheng, Wanli; Kao, Yu Hsun; Chen, Shih Ann; Chen, Yi Jen

doi:10.1016/j.ijcard.2016.06.009

Cited by 28 publications

(29 citation statements)

References 174 publications

(207 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oncocardiology is a new field of clinical medicine that addresses the close link between cancer and cardiovascular diseases [35, 36]. Recent evidence showed that cancer is closely related to the development of AF.…”

Section: Discussionmentioning

confidence: 99%

Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis

Yuan

Zhang

Tse

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

Aims. Previous studies have demonstrated epidemiological evidence for an association between cancer and the development of new-onset atrial fibrillation (AF). However, these results have been conflicting. This systematic review and meta-analysis was conducted to examine the relationship between cancer and the risk of developing atrial fibrillation. Methods. PubMed and Web of Science were searched for publications examining the association between cancer and atrial fibrillation risk published until June 2017. Adjusted odds ratios (ORs) or hazard ratios (HRs) and 95% CI were extracted and pooled. Results. A total of five studies involving 5,889,234 subjects were included in this meta-analysis. Solid cancer patients are at higher risk developing atrial fibrillation compared to noncancer patients (OR 1.47, 95% CI 1.31 to 1.66, p<0.00001; I2 = 67%, p=0.02). The risk of atrial fibrillation was highest within 90 days of cancer diagnosis (OR 7.62, 95% CI 3.08 to 18.88, p<0.00001) and this risk diminished with time. Conclusions. The risk of AF was highest within 90 days of cancer diagnosis. We should take into account the increased risk of atrial fibrillation development and, after this, study the embolic risk and potential indication of oral anticoagulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis

Yuan

Zhang

Tse

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Besides patients with known heart disease, a high rate of AF is reported in the oncologic setting [2]. As reported in the literature, there is a high rate of AF incidence among patients with cancer, a condition which poses relevant prognostic and therapeutic implications [3][4][5][6][7]. Even with considering the improvement in cancer therapy and survival rates, this associated comorbidity represents a relevant public health condition, due to cancer epidemiology and an aging population.…”

Section: Introductionmentioning

confidence: 99%

Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology

Fabiani

Colombo

Bacchiani

et al. 2019

JCM

View full text Add to dashboard Cite

Atrial fibrillation (AF) is a common supraventricular arrhythmia, a recognized risk factor for ischemic stroke, as a potential driver for heart failure (HF). Cancer patients have an increased risk for AF, even not including any cancer-specific treatment, as surgery or chemotherapy. The mechanism is multifactorial, with inflammation and changes in autonomic tone as critical actors. Commonly, AF is a recurrent complication of the post-operative period in cancer surgery (especially thoracic). Recent papers confirmed a significant incidence of post-operative (non-cardiac surgery) AF (PAF), partially mitigated by the use of prophylactic (rate o rhythm control) treatments. A relevant difference, in terms of mean hospitalization time, emerges between patients developing PAF and those who do not, while long term impact remains a matter of debate, due to several potential confounding factors. Besides clinical predictors, structural (i.e., echocardiographic) and bio-humoral findings may help in risk prediction tasks. In this respect, pre-operative natriuretic peptides (NPs) concentrations are nowadays recognized as significant independent predictors of perioperative cardiovascular complications (including PAF), while elevated post-operative levels may further enhance risk stratification. The aim of the present paper is to trace the state of the art in terms of incidence, management, prevention, and outcome of PAF in the field of thoracic surgical oncology.

show abstract

“…The growing interest in cardio-oncology (the field of cardiovascular disease in patients with cancer) 1,2,3 has been accompanied by concerns about an increased risk of developing atrial fibrillation (AF) following cancer diagnosis, 4,5,6,7,8,9,10,11,12,13,14,15 as well as a higher risk of cancer following the recognition of AF. 15,16,17,18,19,20 In fact, AF has been proposed as a marker of an occult malignant neoplasm.…”

Section: Introductionmentioning

confidence: 99%

Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation

et al. 2019

View full text Add to dashboard Cite

show abstract

Pathophysiology of cancer therapy-provoked atrial fibrillation

Cited by 28 publications

References 174 publications

Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis

Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis

Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology

Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation

Contact Info

Product

Resources

About